Abstract
Irritable bowel syndrome is the most common functional gastrointestinal disorder characterized by chronic abdominal pain or discomfort in association with a change in bowel habit. 5-HT receptor modulators have been developed as IBS therapeutic agents and proved to be effective in the treatment of the disease. In this letter, 12 berberine derivatives were designed and synthesized as 5-HT receptor modulators. Preliminary biological tests suggested that the new compounds exhibited promising activity for IBS therapy.
Keywords: Irritable bowel syndrome (IBS), Berberine Derivatives, gastrointestinal (GI) disorder, intestinal flora, plasma 5-HT, CMC-Na solution, isoquinoline alkaloid, tetrahydroberineper
Letters in Drug Design & Discovery
Title:Synthesis and Biological Evaluation of Berberine Derivatives as IBS Modulator
Volume: 9 Issue: 5
Author(s): Xin Deng, Xinxin Zhao, Jing Han, Jingjie Wang, Wenlong Huang, Hai Qian, Liang Ge
Affiliation:
Keywords: Irritable bowel syndrome (IBS), Berberine Derivatives, gastrointestinal (GI) disorder, intestinal flora, plasma 5-HT, CMC-Na solution, isoquinoline alkaloid, tetrahydroberineper
Abstract: Irritable bowel syndrome is the most common functional gastrointestinal disorder characterized by chronic abdominal pain or discomfort in association with a change in bowel habit. 5-HT receptor modulators have been developed as IBS therapeutic agents and proved to be effective in the treatment of the disease. In this letter, 12 berberine derivatives were designed and synthesized as 5-HT receptor modulators. Preliminary biological tests suggested that the new compounds exhibited promising activity for IBS therapy.
Export Options
About this article
Cite this article as:
Xin Deng, Xinxin Zhao, Jing Han, Jingjie Wang, Wenlong Huang, Hai Qian, Liang Ge , Synthesis and Biological Evaluation of Berberine Derivatives as IBS Modulator, Letters in Drug Design & Discovery 2012; 9 (5) . https://dx.doi.org/10.2174/157018012800389386
DOI https://dx.doi.org/10.2174/157018012800389386 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The State of the Problem of Achieving Extremely Low LDL Levels
Current Pharmaceutical Design Conference Report: 14th International Congress on Amino Acids, Peptides and Proteins, Vienna, Austria, August 3-7, 2015
CNS & Neurological Disorders - Drug Targets Unusual Clinical Manifestations of the Antiphospholipid Syndrome
Current Rheumatology Reviews Moderate Wine Consumption in the Prevention of Metabolic Syndrome and its Related Medical Complications
Endocrine, Metabolic & Immune Disorders - Drug Targets The Updated Role of Oxidative Stress in Subarachnoid Hemorrhage
Current Drug Delivery Metalloproteinases and Metalloproteinase Inhibitors in Age-Related Diseases
Current Pharmaceutical Design HIV-1-Associated Dementia During HAART Therapy
Recent Patents on CNS Drug Discovery (Discontinued) Lipid Biomarkers in Alzheimer's Disease
Current Alzheimer Research Bedtime Hypertension Chronotherapy: Concepts and Patient Outcomes
Current Pharmaceutical Design Blood-Brain Barrier Integrity and Glial Support: Mechanisms that can be Targeted for Novel Therapeutic Approaches in Stroke
Current Pharmaceutical Design Sigma-1 Receptors: Potential Targets for the Treatment of Substance Abuse
Current Pharmaceutical Design Neuroprotective Effects of Heat Shock Protein70
CNS & Neurological Disorders - Drug Targets Pharmacological Treatment of Hypertension in Pregnancy
Current Pharmaceutical Design Anticoagulation in Patients with Heparin-Induced Thrombocytopenia undergoing Percutaneous Coronary Angiography and Interventions
Current Pharmaceutical Design Stroke and Vascular Cognitive Impairment: The Role of Intestinal Microbiota Metabolite TMAO
CNS & Neurological Disorders - Drug Targets Association of SORL1 Alleles with Late-Onset Alzheimer's Disease. Findings from the GIGAS_LOAD Study and Mega-Analysis
Current Alzheimer Research G-Lymphatic, Vascular and Immune Pathways for Aβ Clearance Cascade and Therapeutic Targets For Alzheimer’s Disease
Combinatorial Chemistry & High Throughput Screening Targeting the Alpha 7 Nicotinic Acetylcholine Receptor to Reduce Amyloid Accumulation in Alzheimers Disease Pyramidal Neurons
Current Pharmaceutical Design Rashes, Sniffles, and Stroke: A Role for Infection in Ischemic Stroke of Childhood
Infectious Disorders - Drug Targets Therapeutic Nucleic Acids
Recent Patents on Regenerative Medicine